Literature DB >> 2273598

[Bucillamine-associated membranous nephropathy in a patient with rheumatoid arthritis].

M Kawano1, H Nomura, Y Iwainaka, A Nakashima, I Koni, Y Tofuku, R Takeda.   

Abstract

A case of bucillamine-associated membranous nephropathy in a patient with rheumatoid arthritis was reported. A 34 year-old woman was admitted to our hospital because of proteinuria in September, 1988. Rheumatoid arthritis had been diagnosed in April, 1988, and had been treated with bucillamine (disease modifying anti rheumatic drug) and amfenac (nonsteroidal antiinflammatory drug). The renal biopsy specimens showed Stage I membranous nephropathy, on both electron and immunofluorescence microscopy. Proteinuria decreased after the drugs were withdrawn despite continued RA symptoms. These results were consistent with drug induced nephropathy. Since bucillamine has some resemblances in its structure and pharmacologic action to D-penicillamine, which sometimes induces membranous nephropathy, it is thought that the nephropathy in this case was caused by an adverse reaction to bucillamine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2273598

Source DB:  PubMed          Journal:  Nihon Jinzo Gakkai Shi        ISSN: 0385-2385


  1 in total

Review 1.  Bucillamine (a new therapeutic agent for rheumatoid arthritis) induced nephrotic syndrome: a report of two cases and review of the literature.

Authors:  T Isozaki; M Kimura; N Ikegaya; T Arai; Y Fujigaki; A Hishida; E Kaneko
Journal:  Clin Investig       Date:  1992-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.